Putting Patients First Blog

JUNE 26, 2025

The NHC supports the efforts to reduce out-of-pocket costs for Medicare beneficiaries and appreciates CMS’ work to establish a process that seeks to incorporate patient perspectives into drug pricing policy. Even well-intentioned policies can create access disparities if communication and operational support are lacking.

Drug Pricing 52

Drug Pricing Communication Drug Development Documentation 52

Putting Patients First Blog

JULY 2, 2024

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP).

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling HIPAA 52

Putting Patients First Blog

SEPTEMBER 3, 2024

Overall, while the NHC appreciates CMS’ intent to streamline the data submission process and make it more accessible, we encourage ongoing dialogue and adjustments to ensure that the process remains patient-centered, efficient, and capable of capturing the full spectrum of information necessary to inform meaningful drug price negotiations.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling Communication 52

Putting Patients First Blog

JANUARY 27, 2025

This includes clear communication about how AI tools are used in clinical and administrative Transparency fosters trust and empowers patients and providers to actively participate in care decisions. Comprehensive Transparency: AI applications should be fully disclosed, explainable, and accessible to patients and providers in layperson terms.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

Pharmaceutical Technology

JANUARY 16, 2023

The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Similar echoes are heard in Europe, where pressure to curb price growth will stay a priority.

Drug Pricing 64

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 64

Big Molecule Watch

JANUARY 10, 2025

On August 15, 2024 , the Centers for Medicare & Medicaid Services (“CMS”) announced the negotiated maximum fair prices for the 10 drugs. The reductions in price ranged from 38 to 79 percent of the 2023 listed prices for the drugs. These new prices will take effect starting January 1, 2026.

Biosimilars 45

Biosimilars Drug Pricing Labelling Communication 45

Pharmaceutical Technology

JANUARY 16, 2023

The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Similar echoes are heard in Europe, where pressure to curb price growth will stay a priority.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52